HSP90 and the chaperoning of cancer
The DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Standing watch over the proteome, molecular chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival. This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution. Pharmacologically 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HSP90AB1 is commonly overexpressed in a variety of cancers, with this upregulation typically linked to poor prognostic outcomes and increased resistance to standard chemotherapy and radiotherapy treatments [12, 42, 43].”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [43]
In the citing paper
“This role as a potentiator for genetic variation has been observed in fungi as well as mammalian cancer cells20,88,135,136.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
In the citing paper
“Second, Hsp90 can enable the phenotypic effects of new mutations either by stabilizing mutant regulators or by stabilizing non-mutant regulators that mediate signalling required for adaptation.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
Citations
Cites
Hsp90 as a capacitor for morphological evolution
Rutherford, S. L., & Lindquist, S. (1998) · Nature · doi:10.1038/24550 · Cited by 2,270 · cited 1×
“melanogaster and Arabidopsis thaliana model systems that HSP90 can conceal inherent genetic variation within populations of organism”
BackgroundSelf-citationWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Self-citationA high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387 · cited 1×
“By contrast, in normal cells, there is a substantial pool of free HSP90 dimers that have low ATPase activity and low drug affinit”
BackgroundHsp90 as a capacitor of phenotypic variation
Queitsch, C., Sangster, T. A., & Lindquist, S. (2002) · Nature · doi:10.1038/nature749 · Cited by 1,372
Self-citationStebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1997) · Cell · doi:10.1016/s0092-8674(00)80314-1 · Cited by 1,265
Structure of TPR Domain–Peptide Complexes
Scheufler, C., Brinker, A., Bourenkov, G., Pegoraro, S., Moroder, L., Bartunik, H., Hartl, F. U., & Moarefi, I. (2000) · Cell · doi:10.1016/s0092-8674(00)80830-2 · Cited by 1,188
Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death
Jolly, C. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1564 · Cited by 1,048 · cited 1×
“Several detailed reviews are available that address the molecular and cellular biology of the heat-shock respons”
BackgroundThe 90-kDa Molecular Chaperone Family
Csermely, P., Schnaider, T., So″ti, C., Prohászka, Z., & Nardai, G. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00013-8 · Cited by 1,028
Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004 · cited 1×
“Drug binding at the N-terminus of HSP90 has now been shown to alter many of its normal function”
Background
Research works printed but not linked: 2
- McCollum, A., Toft, D. O. & Erlichman, C. Geldanamycin enhances cisplatin cytotoxicity through loss of Akt activation in A549 cells. Clin. Cancer Res. 9 (Suppl.), 6178 (2003).
- Barbosa, J. A. et al. Discovery of novel small molecule Hsp90 complex inhibitors using a forward chemical genetics approach. Clin. Cancer Res. 9 (Suppl.), 6176 (2003).
Cited by
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
“Heat-shock protein 90 (Hsp90) is an abundant cellular chaperone whose overexpression in tumour cells correlates with poor prognosis and resistance to chemotherap”
BackgroundIntra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyak, K. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3261 · Cited by 2,000
HSP90 at the hub of protein homeostasis: emerging mechanistic insights
Taipale, M., Jarosz, D. F., & Lindquist, S. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2918 · Cited by 1,818
“Structurally unrelated natural product inhibitors of HSP90 displace ATP and block HSP90 function with high specificit”
BackgroundSelf-citationPrinciples of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
“tumors (Whitesell and Lindquist, 2005) and is therefore a potential NOA target (Figure 2).”
InfluentialCholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626
“HSP90 is a molecular chaperone required for essential cellular house keeping functions, such as protein folding and mediating posttranslational protein homeostasis, as well as for maintenance of oncoprotein stability 109 .”
Schopf, F. H., Biebl, M. M., & Buchner, J. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.20 · Cited by 1,540
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Targeting the dynamic HSP90 complex in cancer
Trepel, J., Mollapour, M., Giaccone, G., & Neckers, L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2887 · Cited by 1,514
“Therefore, HSP90 is recognized as a crucial facilitator of oncogene addiction and cancer cell surviva”
BackgroundFever and the thermal regulation of immunity: the immune system feels the heat
Evans, S. S., Repasky, E. A., & Fisher, D. T. (2015) · Nature Reviews Immunology · doi:10.1038/nri3843 · Cited by 1,257
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Apoptosis and Molecular Targeting Therapy in Cancer
Hassan, M., Watari, H., AbuAlmaaty, A., Ohba, Y., & Sakuragi, N. (2014) · BioMed Research International · doi:10.1155/2014/150845 · Cited by 1,121
“Conflict of Interests The authors declare that there is no conflict of interests regarding the publication of this paper.”
BackgroundRetractedThe unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy
Doane, T. L., & Burda, C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15260f · Cited by 1,098
Effects of Aneuploidy on Cellular Physiology and Cell Division in Haploid Yeast
Torres, E. M., Sokolsky, T., Tucker, C. M., Chan, L. Y., Boselli, M., Dunham, M. J., & Amon, A. (2007) · Science · doi:10.1126/science.1142210 · Cited by 935
Histone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 874
“HDAC inhibition results in loss of HSP90 chaperone function and enhanced degradation of BCR-ABL, human epidermal growth factor receptor 2/neu, and FLT3; these data suggest potential synergy of HDAC inhibitors with imatinib, traztuzumab, or FLT3 inhibitors in cancers driven by amplified or mutated tyrosine kinases.(47)”
BackgroundProteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging
Morimoto, R. I. (2008) · Genes & Development · doi:10.1101/gad.1657108 · Cited by 872
“…can influence the conformation and activities of a wide range of substrates such as p53 (Blagosklonny et al. 1996), HSF1 (Shi et al. 1998), and other transcription factors including steroid aporeceptors, in addition to kinases and phosphatases (Pratt and Toft 2003; Whitesell and Lindquist 2005).”
BackgroundRegulation of heat shock transcription factors and their roles in physiology and disease
Gomez-Pastor, R., Burchfiel, E. T., & Thiele, D. J. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.73 · Cited by 849
Heat Shock Factor 1 Is a Powerful Multifaceted Modifier of Carcinogenesis
Dai, C., Whitesell, L., Rogers, A. B., & Lindquist, S. (2007) · Cell · doi:10.1016/j.cell.2007.07.020 · Cited by 826
“When misfolding exceeds a certain threshold, other HSPs disaggregate proteins and refold them or divert them to the proteasome for destruction (Whitesell and Lindquist, 2005).”
BackgroundInfluentialSelf-citationMechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 705
Heat Shock Proteins and Cancer
Wu, J., Liu, T., Rios, Z., Mei, Q., Lin, X., & Cao, S. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.11.009 · Cited by 696
Mendillo, M. L., Santagata, S., Koeva, M., Bell, G. W., Hu, R., Tamimi, R. M., Fraenkel, E., Ince, T. A., Whitesell, L., & Lindquist, S. (2012) · Cell · doi:10.1016/j.cell.2012.06.031 · Cited by 694
“These include elevated temperatures, oxidative agents, heavy metals, and low pH. Organisms respond by inducing heat-shock proteins (HSPs), which act as molecular chaperones to restore protein homeostasis (Shamovsky and Nudler, 2008; Whitesell and Lindquist, 2005).”
BackgroundSelf-citationThe role of protein clearance mechanisms in organismal ageing and age-related diseases
Vilchez, D., Saez, I., & Dillin, A. (2014) · Nature Communications · doi:10.1038/ncomms6659 · Cited by 689
The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease
Hoter, A., El-Sabban, M. E., & Naim, H. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092560 · Cited by 693
“They exist in all living kingdoms except for archaea [6] and represent about 1–2% of the total mammalian cellular proteins under non-stress conditions [7].”
BackgroundPrabhakar, N. R., & Semenza, G. L. (2012) · Physiological Reviews · doi:10.1152/physrev.00030.2011 · Cited by 641
“Heat shock protein 90 (HSP90) is a molecular chaperone that protects client proteins from misfolding and degradation (349).”
BackgroundWang, T., Yu, H., Hughes, N. W., Liu, B., Kendirli, A., Klein, K., Chen, W. W., Lander, E. S., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.01.013 · Cited by 632
“Indeed, chaperones, such as Hsp90, act as ‘‘genetic hubs’’ and show epistasis with hundreds of client proteins, including several oncogenic kinases (Whitesell and Lindquist, 2005).”
Hieronymus, H., Lamb, J., Ross, K. N., Peng, X. P., Clement, C., Rodina, A., Nieto, M., Du, J., Stegmaier, K., Raj, S. M., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.005 · Cited by 624
“Only two other existing drugs, cisplatin and novobiocin, act directly on HSP90 outside this fold by binding the C-terminal domain, and even these only induce HSP90 inhibition at high concentrations at which other mechanisms of action likely predominate (Marcu et al., 2000; Whitesell and Lindquist, 2005 ).”
InfluentialWidespread macromolecular interaction perturbations in human genetic disorders
Sahni, N., Yi, S., Taipale, M., Fuxman Bass, J. I., Coulombe-Huntington, J., Yang, F., Peng, J., Weile, J., Karras, G. I., Wang, Y., et al. (2015) · Cell · doi:10.1016/j.cell.2015.04.013 · Cited by 594
“Since chaperones and associated quality control factors (QCFs) can salvage unstable proteins by assisting with folding, and an increase in protein-chaperone interactions (PCIs) has been observed for a number of disease mutants (Whitesell and Lindquist, 2005), our systematic approach begins with characterizing PCIs for…”
Self-citationIntracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy
Schmitt, E., Gehrmann, M., Brunet, M., Multhoff, G., & Garrido, C. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306167 · Cited by 573
“This effect might result from the increase in protein misfolding that is induced by 17-AAG, coupled to the impaired clearance of proteins by the ubiquitin-proteasome pathway [91, 92].”
Background(2011) · PubMed Central · Cited by 560
Molecular mechanisms of proteasome assembly
Murata, S., Yashiroda, H., & Tanaka, K. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2630 · Cited by 546
“Hsp90, the most abundant molecular chaperone known to assist in protein folding and cell signallin”
BackgroundGain of function of mutant p53 by coaggregation with multiple tumor suppressors
Xu, J., Reumers, J., Couceiro, J. R., De Smet, F., Gallardo, R., Rudyak, S., Cornelis, A., Rozenski, J., Zwolinska, A., Marine, J.-C., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.546 · Cited by 543
“To study the effect of p53 aggregates on the expression level of two important cancer-related chaperones Hsp70 and Hsp90 (ref”
Backgroundα-Synuclein: Membrane Interactions and Toxicity in Parkinson's Disease
Auluck, P. K., Caraveo, G., & Lindquist, S. (2010) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.042308.113313 · Cited by 519
Self-citationAnticancer compounds derived from fungal endophytes: their importance and future challenges
Kharwar, R. N., Mishra, A., Gond, S. K., Stierle, A., & Stierle, D. (2011) · Natural Product Reports · doi:10.1039/c1np00008j · Cited by 530
WORKMAN, P., BURROWS, F., NECKERS, L., & ROSEN, N. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1391.012 · Cited by 521
Cellular Strategies of Protein Quality Control
Chen, B., Retzlaff, M., Roos, T., & Frydman, J. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004374 · Cited by 502
Amm, I., Sommer, T., & Wolf, D. H. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.06.031 · Cited by 493
Cellular Heterogeneity and Molecular Evolution in Cancer
Almendro, V., Marusyk, A., & Polyak, K. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163923 · Cited by 498
“Finally, many tumors display activation of heat shock responses (32), and because heat shock proteins have been implicated in the so-called canalization of phenotypes (33), saturation of heat shock responses can cause mutations that would be silent under normal circumstances to produce phenotypes.”
BackgroundLiu, Y. V., Baek, J. H., Zhang, H., Diez, R., Cole, R. N., & Semenza, G. L. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.01.001 · Cited by 478
“HIF-1α degradation is regulated in an O2independent manner by heat shock protein 90 (HSP90), a molecular chaperone that protects client proteins from misfolding and degradation (Neckers and Ivy, 2003; Whitesell and Lindquist, 2005).”
BackgroundInfluentialDrug discovery approaches targeting the PI3K/Akt pathway in cancer
Garcia-Echeverria, C., & Sellers, W. R. (2008) · Oncogene · doi:10.1038/onc.2008.246 · Cited by 473
“Inhibitors of the ATPase activity of heat–shock protein 90 Heat–shock proteins are ATP-dependent molecular chaperones involved in the folding, stability, activation and cellular localization of a selected range of substrates, the so-called ‘client proteins’ (Whitesell and Lindquist, 2005).”
BackgroundEccles, S. A., Massey, A., Raynaud, F. I., Sharp, S. Y., Box, G., Valenti, M., Patterson, L., de Haven Brandon, A., Gowan, S., Boxall, F., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5256 · Cited by 479
Diverse Cellular Functions of the Hsp90 Molecular Chaperone Uncovered Using Systems Approaches
McClellan, A. J., Xia, Y., Deutschbauer, A. M., Davis, R. W., Gerstein, M., & Frydman, J. (2007) · Cell · doi:10.1016/j.cell.2007.07.036 · Cited by 474
“The recent identification of Hsp90 as a promising target for anticancer therapies also highlights the practical implications of understanding the extent of chaperone function in the cell (Whitesell and Lindquist, 2005).”
BackgroundCombining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G., & Postel-Vinay, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0267-4 · Cited by 445
Targeting heat shock proteins in cancer
Jego, G., Hazoumé, A., Seigneuric, R., & Garrido, C. (2013) · Cancer Letters · doi:10.1016/j.canlet.2010.10.014 · Cited by 452
Shiau, A. K., Harris, S. F., Southworth, D. R., & Agard, D. A. (2006) · Cell · doi:10.1016/j.cell.2006.09.027 · Cited by 455
“Since many hsp90 client proteins play critical roles in cellular proliferation and survival, pharmacologic suppression of hsp90 activity, and hence the many hsp90-dependent signaling pathways, blocks growth of cancerous cells (Whitesell and Lindquist, 2005).”
BackgroundBrough, P. A., Aherne, W., Barril, X., Borgognoni, J., Boxall, K., Cansfield, J. E., Cheung, K.-M. J., Collins, I., Davies, N. G. M., Drysdale, M. J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701018h · Cited by 444
Regulation of Tumor Cell Mitochondrial Homeostasis by an Organelle-Specific Hsp90 Chaperone Network
Kang, B. H., Plescia, J., Dohi, T., Rosa, J., Doxsey, S. J., & Altieri, D. C. (2007) · Cell · doi:10.1016/j.cell.2007.08.028 · Cited by 443
“In tumor cells, Hsp90 is thought to orchestrate a broad cell-survival program (Isaacs et al., 2003; Whitesell and Lindquist, 2005), which has been linked to stabilization of cell viability effectors (Sato et al., 2000), adaptation to unfavorable environments (Beere, 2004), and inhibition of…”
BackgroundThe Hsp90 molecular chaperone: an open and shut case for treatment
Pearl, L. H., Prodromou, C., & Workman, P. (2008) · Biochemical Journal · doi:10.1042/bj20071640 · Cited by 447
Genetic Interactions in Cancer Progression and Treatment
Ashworth, A., Lord, C. J., & Reis-Filho, J. S. (2011) · Cell · doi:10.1016/j.cell.2011.03.020 · Cited by 426
“Molecular chaperones facilitate protein folding and aggregation in normal cells, and in tumor cells HSP90 probably suppresses some of the deleterious effects of a highly mutated proteome, acting as a form of genetic capacitor (Whitesell and Lindquist, 2005).”
Xie, M., Yu, T., Jing, X., Ma, L., Fan, Y., Yang, F., Ma, P., Jiang, H., Wu, X., Shu, Y., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01208-3 · Cited by 429
Successful Applications of Computer Aided Drug Discovery: Moving Drugs from Concept to the Clinic
Talele, T., Khedkar, S., & Rigby, A. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790232251 · Cited by 407
“The molecular chaperone heat shock protein 90 (HSP90) supports the correct conformation, stabilization, activation, and localization of ‘‘client’’ proteins, many of which are involved in tumor progression, hence HSP90 is an ideal and novel target in cancer therapy [71-74].”
BackgroundThe Heat Shock Response: Systems Biology of Proteotoxic Stress in Aging and Disease
Morimoto, R. I. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2012.76.010637 · Cited by 407
Azaphilones: Chemistry and Biology
Gao, J.-M., Yang, S.-X., & Qin, J.-C. (2013) · Chemical Reviews · doi:10.1021/cr300402y · Cited by 409
Cowen, L. E., Singh, S. D., Köhler, J. R., Collins, C., Zaas, A. K., Schell, W. A., Aziz, H., Mylonakis, E., Perfect, J. R., Whitesell, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813394106 · Cited by 413
“These Hsp90 inhibitors bind with high affinity to Hsp90’s unusual ATP binding pocket, thereby inhibiting ATP-dependent chaperone function (18, 25).”
BackgroundSelf-citationAneuploidy: Cells Losing Their Balance
Torres, E. M., Williams, B. R., & Amon, A. (2008) · Genetics · doi:10.1534/genetics.108.090878 · Cited by 407
“…to drugs that interfere with proteasome function (Torres et al. 2007) and with the observation that cancer cells, which are frequently aneuploid, depend on high proteasome activity since they are more sensitive to proteasome inhibitors than euploid cells (reviewed in Whitesell and Lindquist 2005).”
BackgroundCrosstalk between Hsp90 and Hsp70 Chaperones and Heat Stress Transcription Factors in Tomato
Hahn, A., Bublak, D., Schleiff, E., & Scharf, K.-D. (2011) · The Plant Cell · doi:10.1105/tpc.110.076018 · Cited by 396
“…inhibited by binding geldanamycin (GDA) to the ATP binding pocket of the chaperone and preventing the stabilization of client protein interaction (Whitesell and Lindquist, 2005; Pearl et al., 2008), we used this drug to analyze the endogenous Hsfs in tomato suspension culture cells (Figure 6).”
BackgroundMethodCritical roles of non-histone protein lysine methylation in human tumorigenesis
Hamamoto, R., Saloura, V., & Nakamura, Y. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3884 · Cited by 376
Survivin and IAP proteins in cell-death mechanisms
Altieri, D. C. (2010) · Biochemical Journal · doi:10.1042/bj20100814 · Cited by 376
LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc
Tang, J., Yan, T., Bao, Y., Shen, C., Yu, C., Zhu, X., Tian, X., Guo, F., Liang, Q., Liu, Q., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11447-8 · Cited by 372
Link Between m6A Modification and Cancers
Liu, Z.-X., Li, L.-M., Sun, H.-L., & Liu, S.-M. (2018) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2018.00089 · Cited by 373
“, 2014), a molecular chaperone maintains the stability of many tumor-promoting oncoproteins (Whitesell and Lindquist, 2005).”
BackgroundNon-Oncogene Addiction and the Stress Phenotype of Cancer Cells
Solimini, N. L., Luo, J., & Elledge, S. J. (2007) · Cell · doi:10.1016/j.cell.2007.09.007 · Cited by 365
“One plausible mechanism by which HSF1 functions is through the induction of the heat-shock protein HSP90, which has been implicated in tumorigenesis and is overexpressed in a variety of cancers (Whitesell and Lindquist, 2005).”
BackgroundProtein Quality Control by Molecular Chaperones in Neurodegeneration
Ciechanover, A., & Kwon, Y. T. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00185 · Cited by 346
“Structural studies have shown that Hsp90 is composed of an N-terminal ATP-binding domain (N-domain), a mid-domain that binds the substrate (Mdomain), and a C-terminal dimerization domain (C-domain) (Picard, 2002; Whitesell and Lindquist, 2005; Taipale et al., 2010; Finka and Goloubinoff, 2013).”
BackgroundRegulation and function of the human HSP90AA1 gene
Zuehlke, A. D., Beebe, K., Neckers, L., & Prince, T. (2015) · Gene · doi:10.1016/j.gene.2015.06.018 · Cited by 347
“…2008). the human HSP90AA1 gene, Gene (2015), http://dx.doi.org/10.1016/ Hsp90 comprises 1–2% of cellular protein in unstressed cells and up to 4–6% in the presence of stress (Picard, 2002; Whitesell and Lindquist, 2005; Stravopodis et al., 2007; Taipale et al., 2010; Finka and Goloubinoff, 2013).”
BackgroundInfluentialImproving survival by exploiting tumour dependence on stabilized mutant p53 for treatment
Alexandrova, E. M., Yallowitz, A. R., Li, D., Xu, S., Schulz, R., Proia, D. A., Lozano, G., Dobbelstein, M., & Moll, U. M. (2015) · Nature · doi:10.1038/nature14430 · Cited by 354
Mitochondrial PKM2 regulates oxidative stress-induced apoptosis by stabilizing Bcl2
Liang, J., Cao, R., Wang, X., Zhang, Y., Wang, P., Gao, H., Li, C., Yang, F., Zeng, R., Wei, P., et al. (2017) · Cell Research · doi:10.1038/cr.2016.159 · Cited by 350
Dissection of the ATP-induced conformational cycle of the molecular chaperone Hsp90
Hessling, M., Richter, K., & Buchner, J. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1565 · Cited by 349
Inhibition of HSP90 molecular chaperones: moving into the clinic
Garcia-Carbonero, R., Carnero, A., & Paz-Ares, L. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70169-4 · Cited by 351
Widespread Regulation of Translation by Elongation Pausing in Heat Shock
Shalgi, R., Hurt, J. A., Krykbaeva, I., Taipale, M., Lindquist, S., & Burge, C. B. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.11.028 · Cited by 339
“For example, elevated levels of chaperones are often observed in cancer (Mosser and Morimoto, 2004; Whitesell and Lindquist, 2005).”
BackgroundSelf-citationProteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy
Deshaies, R. J. (2014) · BMC Biology · doi:10.1186/s12915-014-0094-0 · Cited by 337
“Other reviews have focused specifically on targeting chaperones or autophagy as a means to treat cancer [11,12].”
BackgroundGoing the Extra (Synaptic) Mile: Excitotoxicity as the Road Toward Neurodegenerative Diseases
Armada-Moreira, A., Gomes, J. I., Pina, C. C., Savchak, O. K., Gonçalves-Ribeiro, J., Rei, N., Pinto, S., Morais, T. P., Martins, R. S., Ribeiro, F. F., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00090 · Cited by 317
“Studies have been performed with a Hsp90B inhibitor (17AAG), which is one of the proteins that recruit GLT-1 for degradation (Whitesell and Lindquist, 2005).”
Li, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336
“Highly specific Hsp90 inhibitors such as the geldanamycin and its clinically active derivative, the prototype 17AAG, competitively bind to the N-terminal ATP-binding pocket and stop the chaperone cycle, leading to client protein degradation.(26,27) Indeed, 17AAG alone shows similar preferential efficacy in mutp53 tumo…”
Synthetic lethality: General principles, utility and detection using genetic screens in human cells
Nijman, S. M. B. (2011) · FEBS Letters · doi:10.1016/j.febslet.2010.11.024 · Cited by 319
“Capacitors may also explain the effectiveness of HSP90 and histone deacetylase inhibitors as anticancer drugs, a topic that is discussed below [19].”
BackgroundThe Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases
Saez, I., & Vilchez, D. (2014) · Current Genomics · doi:10.2174/138920291501140306113344 · Cited by 325
“Upregulation of proteasomal activity eliminates aberrant proteins that otherwise would be toxic for the cell [158].”
BackgroundSequist, L. V., Gettinger, S., Senzer, N. N., Martins, R. G., Jänne, P. A., Lilenbaum, R., Gray, J. E., Iafrate, A. J., Katayama, R., Hafeez, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8338 · Cited by 330
“and survival through its role as a protein chaperone.(1) Hsp90 is an emerging focus of cancer ther-”
BackgroundTargeting HSP90 for cancer therapy
Mahalingam, D., Swords, R., Carew, J. S., Nawrocki, S. T., Bhalla, K., & Giles, F. J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605066 · Cited by 317
“Co-chaperones also recruit specific client proteins to HSP90 and/or stabilise HSP90 in an ATP-bound state to prolong the half-life of the mature multichaperone complex (Whitesell and Lindquist, 2005).”
BackgroundInfluentialVHL and HIF signalling in renal cell carcinogenesis
Baldewijns, M. M., van Vlodrop, I. J., Vermeulen, P. B., Soetekouw, P. M., van Engeland, M., & de Bruïne, A. P. (2010) · The Journal of Pathology · doi:10.1002/path.2689 · Cited by 316
“HIF-1α degradation is also regulated in an oxygen/ PHD/pVHL-independent manner by heat shock protein 90 (HSP90), which protects proteins from misfolding and degradation through its ATPase activity [15].”
BackgroundMechanisms of Hsp90 regulation
Prodromou, C. (2016) · Biochemical Journal · doi:10.1042/bcj20160005 · Cited by 311
Santagata, S., Hu, R., Lin, N. U., Mendillo, M. L., Collins, L. C., Hankinson, S. E., Schnitt, S. J., Whitesell, L., Tamimi, R. M., Lindquist, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115031108 · Cited by 311
“This focus on HSPs in cancer has uncovered their potential as therapeutic targets, with HSP90 inhibitors being the first modulators of chaperone activity to show clinical utility (12, 13).”
BackgroundSelf-citationMassey, A. J., Williamson, D. S., Browne, H., Murray, J. B., Dokurno, P., Shaw, T., Macias, A. T., Daniels, Z., Geoffroy, S., Dopson, M., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1194-3 · Cited by 313
“The Hsp90 chaperone machinery maintains the correct conformation, stability and activity of a wide variety of oncogenic client proteins [17].”
BackgroundInhibitors of the heat shock response: Biology and pharmacology
Powers, M. V., & Workman, P. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.05.040 · Cited by 320
“and modulation of all aspects of the malignant phenotype [5,7,37].”
BackgroundInfluentialWithaferin A targets heat shock protein 90 in pancreatic cancer cells
Yu, Y., Hamza, A., Zhang, T., Gu, M., Zou, P., Newman, B., Li, Y., Gunatilaka, A. A. L., Zhan, C.-G., & Sun, D. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.09.017 · Cited by 316
“binding pocket, whereas novobiocin (and its derivatives) and cisplatin block the C-terminal ATP binding pocket [23,27–31].”
Wang, H., Feng, Z., Wang, Y., Zhou, R., Yang, Z., & Xu, B. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b09783 · Cited by 315
Novobiocin and Additional Inhibitors of the Hsp90 C-Terminal Nucleotide- binding Pocket
Donnelly, A., & Blagg, B. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708786242895 · Cited by 313
Discovering Anti-Cancer Drugs via Computational Methods
Cui, W., Aouidate, A., Wang, S., Yu, Q., Li, Y., & Yuan, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00733 · Cited by 307
“Thus, HSP90 has become a promising target for cancer treatment (Whitesell and Lindquist, 2005; Pearl and Prodromou, 2006; Sharp and Workman, 2006; Workman et al., 2007).”
BackgroundStructure, Function, and Regulation of the Hsp90 Machinery
Biebl, M. M., & Buchner, J. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a034017 · Cited by 304
“Importantly,∼75% of allmutations occur within theDBD that is chaperoned by Hsp90 in the wild-type and mutated variant (Whitesell et al. 1998; Whitesell and Lindquist 2005; Schulz-Heddergott and Moll 2018).”
BackgroundHsp60 Regulation of Tumor Cell Apoptosis
Ghosh, J. C., Dohi, T., Kang, B. H., & Altieri, D. C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705904200 · Cited by 310
Low temperature photothermal therapy: Advances and perspectives
Yang, K., Zhao, S., Li, B., Wang, B., Lan, M., & Song, X. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214330 · Cited by 309
The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype.
Cowen, L. E. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1835 · Cited by 311
Prions, prionoids and protein misfolding disorders
Scheckel, C., & Aguzzi, A. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0011-4 · Cited by 321
Li, D., Marchenko, N. D., Schulz, R., Fischer, V., Velasco-Hernandez, T., Talos, F., & Moll, U. M. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0534 · Cited by 297
“, HER-2), signaling kinases (Bcr-Abl, Akt, and Raf-1), and mutant p53 (8, 22).”
BackgroundInfluentialDual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis
Powers, M. V., Clarke, P. A., & Workman, P. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.002 · Cited by 307
Karagöz, G. E., Acosta-Alvear, D., & Walter, P. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033886 · Cited by 310
McCready, J., Sims, J. D., Chan, D., & Jay, D. G. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-294 · Cited by 297
“tPA and hsp90α weakly interact in both MDAMB231 and HT-1080 cells perhaps because client and chaperone proteins interact transiently [25].”
BackgroundKRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S., & Gil-Bazo, I. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0789-x · Cited by 301
“Therefore, inhibition of heat shock proteins results in blockade of multiple oncogenic signaling pathways in tumor cells [135].”
BackgroundAkt–RSK–S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases
Moritz, A., Li, Y., Guo, A., Villén, J., Wang, Y., MacNeill, J., Kornhauser, J., Sprott, K., Zhou, J., Possemato, A., et al. (2010) · Science Signaling · doi:10.1126/scisignal.2000998 · Cited by 300
“Although defective RTK endocytosis leads to prolonged RTK signaling and has been linked to malignancy (28), the pathways andmolecules targeted remain largely unknown.”
BackgroundSmith, M. C., & Gestwicki, J. E. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2012.10 · Cited by 286
Tyrosine kinase gene rearrangements in epithelial malignancies
Shaw, A. T., Hsu, P. P., Awad, M. M., & Engelman, J. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3612 · Cited by 292
Teo, R. D., Hwang, J. Y., Termini, J., Gross, Z., & Gray, H. B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00400 · Cited by 289
Protein conformational flexibility modulates kinetics and thermodynamics of drug binding
Amaral, M., Kokh, D. B., Bomke, J., Wegener, A., Buchstaller, H. P., Eggenweiler, H. M., Matias, P., Sirrenberg, C., Wade, R. C., & Frech, M. (2017) · Nature Communications · doi:10.1038/s41467-017-02258-w · Cited by 291
Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors
Powers, M. V., & Workman, P. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01324 · Cited by 285
Post-translational modifications of Hsp90 and their contributions to chaperone regulation
Mollapour, M., & Neckers, L. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.07.018 · Cited by 288
“Cancer cells have co-optedHsp90 to serve a crucial role in protecting an array ofmutated and over-expressed oncoproteins from misfolding and degradation [6,7].”
BackgroundTargeting Hsp90: small-molecule inhibitors and their clinical development
Taldone, T., Gozman, A., Maharaj, R., & Chiosis, G. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.015 · Cited by 284
“Moreover, cancer cells are selectively sensitive to pharmacologic Hsp90 inhibitors, and administration of these agents to multiple cancer animal models results in significant antitumor effects associated mostly with little or no target-associated toxicities [1,2,13].”
Background
Metadata
- Authors
- Whitesell, L., & Lindquist, S. L.
- Affiliations
- University of Arizona (US)
- Whitehead Institute for Biomedical Research (US)
- Corresponding author
- Whitesell, Luke
- ORCID
- Whitesell, Luke
- Venue
- Nature Reviews Cancer
- Published
- 2005-09-20
- Volume
- 5
- Issue
- 10
- Pages
- 761-772
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2022531767
- Cited by
- 2,502
- References
- 149
- Citations by year
- 2026: 81 · 2025: 87 · 2024: 83 · 2023: 97 · 2022: 90 · 2021: 113 · 2020: 123 · 2019: 142 · 2018: 99 · 2017: 116 · 2016: 126 · 2015: 152 · 2014: 154 · 2013: 153 · 2012: 167
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- HSP90, molecular chaperones, carcinogenesis, malignant transformation, somatic evolution, protein folding, proteome, anticancer drug targets, chaperone inhibition
- MeSH terms
- Animals, Humans, Neoplasms, Molecular Chaperones, HSP90 Heat-Shock Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.